30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
Trusts & Estates attorney Samantha Heaton explains the serious impact of The SECURE Act on estate pl...
Read More >
A court recently held that the type of contract delivery method did not change the applicability of ...
Read More >
Less than two months apart, two U.S. Courts of Appeal examined the same two issues involving Amazon ...
Read More >
There is no change in the two key issues that have been causing concern to those involved in real es...
Read More >
Warm sunny days and cool evenings entice motorists, bicyclists and pedestrians to get out and about ...
Read More >
Long term businesses in the retirement plan business don’t die overnight. It takes a very long time...
Read More >